Personalized medicine in oncology has reached an inflection point. The advances in diagnostics and increased understanding of cancer biology now allow clinical predictions based upon the molecular characterization of a tumor. Yet, many stakeholders question the utility of those predictions and whether existing frameworks are sufficient to enable a meaningful, and economically stable, step forward in patient outcomes.
To prepare the healthcare system for what many acknowledge is a paradigm shift in the diagnosis and treatment of cancer, Tapestry Networks has convened the Sustainable Predictive Oncology Therapeutics and Diagnostics (SPOT/Dx) Working Group, a multi-stakeholder forum for bringing together key thought leaders and decision makers across the public and private sectors, including clinical and policy experts, regulators, third-party payers, patient advocates, and industry leaders.
Beginning in 2013, participants of SPOT/Dx committed to improving patient outcomes by equipping healthcare leaders with the tools needed to advance the diagnosis and treatment of cancer, clinical decision-making, and the regulatory/reimbursement infrastructure required to support this paradigm shift toward precision medicine. The SPOT/Dx Working Group aimed to identify two or three opportunity areas within this broader mission, understand what is needed to carry recommendations in these areas forward, and develop a pilot plan to test/validate these recommendations. The results of these efforts are outlined below.
SPOT/Dx Working Group topics:
On July 15-16, 2014, the SPOT/Dx working group convened its third meeting in Arlington, Virginia. The group reaffirmed its commitment to cancer patients, outlined a pilot focused on enhancing the quality of future molecular diagnostics, continued to explore the merits of facilitated drug access/outcomes registry programs, and considered what future contribution the SPOT/Dx group could make to accelerate and safeguard the implementation of precision medicine in oncology.
On March 31 and April 1, 2014, SPOT/Dx Working Group convened for its second meeting in Arlington, Virginia. The meeting took place amidst an increasingly dynamic political and economic period for healthcare, where patient need and quality care must contend with resource constraints. On the heels of the newly passed Protecting Access to Medicare Act of 2014, participants discussed the law’s impact on their ability to deliver personalized oncology treatment in a sustainable and valuable way. The meeting was also an opportune time for participants to consider new models for improving molecular diagnostic quality and for harnessing real-world evidence to advance the development and administration of precision oncology and improve patient outcomes. The meeting enabled participants to clarify outstanding concerns and begin shaping roadmaps in service of these topics.
Tapestry Networks has convened the multi-stakeholder Sustainable Predictive Oncology Therapeutics and Diagnostics Working Group (SPOT/Dx WG) to address these challenges and consider new approaches to advance precision medicine in oncology. The group brings together key thought leaders and decision makers from the public and private sectors, including clinical and policy experts, regulators, third-party payers, patient advocates, and industry leaders. Working together through 2014, participants are committed to improving patient outcomes by equipping healthcare leaders with the tools to advance the diagnosis and treatment of cancer, clinical decision-making, and the regulatory/reimbursement infrastructure required to support a sustainable shift toward precision medicine.